热门资讯> 正文
Cel-Sci报告财年业绩
2025-12-30 12:34
- Cel-Sci press release (CVM): FY research and development expenses were $15.9 million, which decreased by approximately $2.3 million, or 13%, compared to the year ended September 30, 2024.
- Net loss available to common shareholders decreased by $2.2 million to approximately $25.4 million for the twelve months ended September 30, 2025 from $27.6 million in fiscal 2024.
- The operating cash expenditures for the year were approximately $17.1 million.
More on Cel-Sci
- Seeking Alpha’s Quant Rating on Cel-Sci
- Historical earnings data for Cel-Sci
- Financial information for Cel-Sci
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。